Kezar Life Sciences Inc. has announced upcoming presentations of clinical trial data for its investigational drug zetomipzomib at major medical conferences in November 2025. Data from the completed Phase 2a PORTOLA trial in patients with autoimmune hepatitis $(AIH)$ will be presented at The Liver Meeting 2025, organized by the American Association for the Study of Liver Disease (AASLD) in Washington, DC. Key findings include that zetomipzomib demonstrated steroid-sparing biochemical remission and meaningful biomarker shifts correlated with clinical responses in AIH patients. Additionally, Kezar will present safety and preliminary efficacy results from the ongoing PALIZADE Phase 2b trial of zetomipzomib in patients with lupus nephritis (LN) at the American Society of Nephrology (ASN) Kidney Week in Houston, TX. At Week 25, 42% of LN patients treated with zetomipzomib 60 mg achieved a urine protein to creatinine ratio of ≤ 0.5, compared to 21% in the placebo group, with reductions in lupus disease activity and anti-dsDNA autoantibody levels. The safety profile was reported to be consistent across dose groups and with previous global studies in LN. The results will be presented at the respective conferences in November 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kezar Life Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251107342037) on November 07, 2025, and is solely responsible for the information contained therein.
Comments